March 25 Quick Takes: Lava flows down on first day after $100.5M IPO; plus Scipher, Eliem, Brii, Bioheng, RiverVest, JSR Life Science and Apnimed

Lava dips on first day after raising $100.5M IPO
Lava Therapeutics B.V. (NASDAQ:LVTX) fell $0.70 to $14.30 in its first day of trading on NASDAQ after raising $100.5 million through the sale of 6.7 million shares at $15 in an IPO. The deal values the γδ bispecifics play at $380.3 million. Lava’s lead program is LAVA-051, a γδ bispecific targeting CD1D that is expected to start a Phase I/II trial this half in hematological malignancies.

Scipher Medicine raises $82 million in series C round
Precision immunology company Scipher Medicine Corp. raised $82 million in a series C round co-led by aMoon and Northpond Ventures. Other investors included Echo Health Ventures, Khosla Ventures and Alumni Ventures...